Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial

Abstract Background Standard therapy for human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors (afatinib, neratinib, and dacomitinib), anti-HER2 antibody drug conjugate (ADC) trastuzumab emtansine, and an e...

Full description

Bibliographic Details
Main Authors: Xinghao Ai, Zhengbo Song, Hong Jian, Zhen Zhou, Zhiwei Chen, Yongfeng Yu, Ziming Li, Shun Lu
Format: Article
Language:English
Published: BMC 2021-09-01
Series:BMC Cancer
Subjects:
Pyrotinib
Thalidomide
Non-small-cell lung cancer
Human epidermal growth factor receptor 2
Protocol
Online Access:https://doi.org/10.1186/s12885-021-08759-8

Internet

https://doi.org/10.1186/s12885-021-08759-8

Similar Items